Genmab — September 2020

[bibob]

God morgen

[transalp]

Go morgen..

[Helge_LarsenPI-redaktør]

Genmab
@Genmab

Join us at ESMO20, for an oral presentation on phase 2 innovaTV 204 study evaluating the investigational tisotumab vedotin in patients with recurrent or metastatic #cervicalcancer. Visit our virtual booth to get more info. https://esmo.org/meetings/esmo-virtual-congress-2020

[E_L]

that link doesn't get you much, you may want to put the link to the tweet?

[E_L]

I was just wondering Helge, I don't know who you normally get the Symphony Health
data from, but should we expect 1 number for Dara, or a split in Dara IV and Dara Faspro?

[Helge_LarsenPI-redaktør]

Sorry..Link to tweet. https://twitter.com/Genmab/status/1305763362077319169

[Helge_LarsenPI-redaktør]

I receive Symphony Health data from pharma- og biotech investors. I dont know anything about af a evnt. split in Dara IV and Dara Faspro.

[E_L]

ok. I guess we find out next week

[Helge_LarsenPI-redaktør]

Yes.

[E_L]

could use some help on the translation of this chinese article on Amivantamab... https://med.sina.cn/article_detail_103_2_89109.html

[Plimsoller]

Sent you a PM E L.

[Plimsoller]

That didn't go to well Hang on - will send you another one.

[E_L]

thanks, got them, similar to what i get with google tranlator, however wasn't sure what that actually means?

[E_L]

Did they get permission to do those 4 trials in China
? is that what they are saying?

[Plimsoller]

I used Google myself (thought you had issued with their translator), but I just asked a Chinese colleague that question, and she said that they are saying that they have permission.

[E_L]

permission for what ? to do the trial?

[Plimsoller]

Yes.

[E_L]

ok, thanks. and thanks to your colleague

[Plimsoller]

No problem. She is quite impressed that a Dutch guy who doesn't speak Chinese found that article

[Plimsoller]